"Human Genome Investors should inquire as to lead plaintiff status prior to January 9, 2012 deadline by contacting Gilman Law at (888) 252-0048."
Naples, FL (PRWEB) December 30, 2011
Gilman Law LLP, a leading national securities law firm, is actively investigating shareholder allegations that Human Genome Sciences, Inc. (“HGS”) and certain of its officers and directors violated the Securities Exchange Act of 1934.
If you purchased or otherwise acquired shares of Human Genome Sciences, Inc. between July 20, 2009 and November 11, 2010 (“Class Period”), including all persons who acquired the common stock of HGS pursuant and/or traceable to the alleged false and misleading registration statements and prospectuses issued in connection with the Company’s July 28, 2009 public offering of 26.7 million shares of common stock at $14 and its December 2, 2009 public offering of 17.8 million shares of common stock at $26.75, you may contact Gilman Law LLP by January 9, 2012 to discuss your rights, including as to recovery of your losses or to obtain additional information.
Based in Rockville, Maryland, HGS, a commercially focused biopharmaceutical company, developed and conducted clinical trials of a their potential new drug, Benlysta, also called belimumab, for the treatment of Systemic Lupus Erythematosus (“SLE”) which is a chronic, life-threatening autoimmune disease.
A shareholders class action lawsuit was commenced in the United States District Court for the District of Maryland. The complaint alleges that during the Class Period, HGS made false and misleading statements concerning the results of their clinical drug trials they conducted concerning Benlysta and the high risks associated with suicide. Investors only learned of these findings after the U.S. Food and Drug Administration posted their analysis on the Internet. Shareholders alleged that after the FDA information was released, the price of HGS’s common stock dropped over 10% from a closing price of $26.48 on November 11, 2010 to close at $23.50 on November 12, 2010. dockets.justia.com/docket/maryland/mddce/8:2011cv03231/195775/ Case No. 2011-cv-195775
A "lead plaintiff" is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as lead plaintiff. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Gilman Law LLP to serve as your counsel in this action.
If you wish to join the HGS’ class action lawsuit filed in the U.S. District Court for the District of Maryland, please visit http://www.investment-losses.com or contact Gilman Law LLP at (888) 252-0048.
For over 30 years, the lawyers at Gilman Law have been involved in all major aspects of securities fraud litigation. The firm specializes in cases involving stock manipulation, securities fraud, and shareholder rights violations. Gilman Law has extensive experience representing both individual and institutional investors in securities class action suits. Gilman Law has recovered over a billion dollars for its clients and can help you recover any losses that you have incurred as a result of HGS’s fraudulent practices. For more information on the HGS’ Investor Class action lawsuit or our other current investigations, please visit http://www.gilmanlawllp.com or http://gilmanlawsecuritiesstocksbondsfraud.com. For a free evaluation of your case, please contact Gilman Law TOLL FREE at (888) 252-0048.
Gilman Law LLP
Beachway Professional Center Tower
3301 Bonita Beach Road
Bonita Springs, FL 34134
Toll Free 888-252-0048